Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Adagene Announced Progress, Expansion Of The Clinical Collaboration Development Program For Its Masked, Anti-CTLA-4 SAFEbody, ADG126 In Combination With Merck's Keytruda (Pembrolizumab), In Patients With Metastatic Microsatellite-stable Colorectal Cancer

Author: Benzinga Newsdesk | February 09, 2024 07:03am

Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab anticipated in 2024 at a medical conference -

Initiated evaluation of 20 mg/kg loading doses of ADG126 in combination with pembrolizumab to explore enhanced efficacy given superior therapeutic index of ADG126 -

Received clearance from China's Center for Drug Evaluation (CDE) to evaluate ADG126 in combination with pembrolizumab -

Posted In: ADAG MRK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist